by David Alcántara | Nov 17, 2022 | News
Limnopharma’s team in collaboration with Prof. Alberto Zafra from the University of Granada has just carried out biodistribution experiments of LIM21 administered in eye drops in pigs. The animals were handled by expert veterinarians at IAVANTE, located in the Health...
by David Alcántara | Nov 17, 2022 | News
Limnopharma signs an agreement with Inoviem Scientific and Hybrigenics (now Aton) to investigate the mode of action of lim21. The agreement covers a 2 step process to establish how lim21 exerts its therapeutic effect. First, the target protein(s) interacting with...
by David Alcántara | Oct 5, 2022 | News
Covirán has formalized this week its direct participation in Limnopharma through a convertible note. From Limnopharma we thank the Covirán Group for its trust and support for our project, which represents a boost and allows us to continue working with the aim of...
by David Alcántara | Jul 5, 2022 | News
Limnopharma has participated in the health section at Alhambra Venture 2022, being awarded as the best startup in the Health & Bio sector. Alhambra Venture is the most important event that connects entrepreneurs and investors in southern Spain. Since 2014,...
by David Alcántara | Jun 21, 2022 | News
The United States Patent and Trademark Office (USPTO) just granted our patent that protects LIM109 and its uses in inflammatory and neurodegenerative diseases. This is an important step in our IP strategy since the USA market is one of the most important ones in the...
